GHP / Biotechnology Awards 2022 25 , Feb22268 MediMusic disrupts the current clinical practice of music therapy by creating a scalable, digital therapeutic and on-demand service. The original focus of MediMusic was purely dementia, but the advent of COVID-19 caused the business to pivot and bring forward a plan aimed at anxiety and pain. This proved beneficial and allowed the company to build a far greater range of partnerships and opportunities than it may have by just focusing on its original strategy. Join us as we learnmore about MediMusic. Best AI-Based Music Neuroscience Solution 2022: MediMusic MediMusic uses artificial intelligence and machine learning to create audio fingerprints that mimic the human brain’s response to music and dispense it as an efficacy-driven medicine for the benefit of various health morbidities. It then auto-creates personalised smart music track sequences that use predictive analysis to reduce heart rate and cortisol, thereby promoting positive endocrine secretions and physiological response. The user response is monitored, for refinement purposes, via the Digital Drip® bio feedback loop, and evidence-based ROI and multiple cost-saving KPIs are provided for healthcare services. A trial by Lancashire Teaching Hospitals NHS Trust demonstrated that MediMusic reduces heart rate up to 25%. As a result of this success, MediMusic has been adopted onto the EDOVATION/ Medicomm programme which gives it access to a further three trusts in Lancashire. It is also soon to be adopted into the Leeds Teaching Hospitals NHS Trust Innovation Village as well as the Social Care Innovation programme run by Hull University and East Riding Council. With MediMusic’s current beachhead being pain, anxiety, and cognitive impairment from dementia, it has been able to show in trial how music reduces anxiety by 43% and subsequent medication usage by 24%, whilst pain reduction is 28% and medication use 14%. In both these trial instances, the music was generalised and not delivered as a service focused on the intent of entraining a physiological response. For this reason, the MediMusic AI and ML process is expected to greatly improve on these outcomes over time. Furthermore, it has been concluded via the MARQUE study that the cost of dementia anxiety to a care home is £1,125; MediMusic can reduce this cost by 86%. Alongside having financial benefits, MediMusic also contributes positively to the environment. The global medicines industry produces 55% more emissions than the car industry, with the NHS having the largest single domestic footprint – representing 5% of the UK total. Of this, 25% is attributable to medicine, with the biggest culprits being painkillers and anxiety drugs. And nitrous oxide gas has an environmental impact 300-times that of CO2. Besides making pain and anxiety medication more performant, the hormone, oxytocin is produced as a by-product of listening to music – which is key to childbirth and a process in which the use of nitrous oxide is prevalent. With regards to the future, MediMusic has several cost benefit RC trials planned in chronic pain, perioperative environments and dementia. In addition, recent trial interest from Harvard University, The Tufts Medical Centre, Boston, and the Beth Israel Deaconess Hospital Boston have widened its options for a launch in North America. Company: MediMusic Contact: Gary Jones Email: [email protected] Website: www.medimusic.co
RkJQdWJsaXNoZXIy MTUyMDQwMA==